We're driven by opportunity and the transformative nature of technology. Our holdings are multi-sector. Non-chemical disinfectants. Audio therapy for tinnitus. Next generation computer memory. Therapeutic devices. Nano-scale fuel cells.
The common thread among our investments: The ability to transform leading-edge research into commercial success. But it takes more than the promise of innovation to earn a place as an Allied Minds subsidiary. Every one of our investments also has an attractive risk-return profile, a deliverable timeline and potential products that will be groundbreaking in their respective fields.
Allied Minds Devices is focused on developing transformative technologies into commercially viable medical device products.
Allied-Bristol Life Sciences LLC is a first-of-its-kind joint venture between Allied Minds and Bristol-Myers Squibb Co. that aims to deliver the important biotech products of tomorrow.
Developing and commercializing transformative breed technology from U.S. federal research institutions.
Biotectix is the leading provider of conducting polymer medical materials.
BridgeSat, Inc. is commercializing the next generation of optical transmission capabilities to enable low latency, high throughput transmission of Low Earth Orbit-originated data to terrestrial ground control stations.
Broadcast Routing Fountains is building a novel Internet architecture that seeks to efficiently and securely leverage broadcast channels for disseminating routing information.
Cephalogics is developing noninvasive, bedside brain monitor to improve outcomes in patients with neurological injury while reducing costs and hospital stays.
CryoXtract offers a suite of automated product solutions that allow the worldwide scientific community to access/r-access valuable frozen biosamples without exposing them to damaging freeze/thaw cycles.
Developing critical enabling technologies for the next-generation of wireless communications by improving supply, demand, and delivery of spectrum for future cellular communications.
Foreland Technologies is a cyber security platform company for the discovery, incubation and commercialization of emerging technologies.
LuxCath is developing a catheter based real-time tissue and lesion visualization technology for use during cardiac ablation procedures.
Novare Pharmaceuticals is a biotechnology company focused on developing therapeutic products that help the body replenish and rebuild itself using its own tissue.
Optio Labs develops mobile security technologies for today’s evolving cyber operating environment.
Percipient Networks produces next generation security technologies for enterprise network defense.
Precision Biopsy is developing a novel medical device platform to provide real-time optical pathology of normal tissue and to minimize unnecessary tissue coring, pathology costs, and patient anxiety.
RF Biocidics seeks to make food safe from insects and pathogens through a process that does not use chemicals, is organic, and does not alter sensory or nutritional characteristics.
SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a portfolio of differentiated best-in-class therapeutics.
Seamless Devices is commercializing novel switched mode signal processing IP that taps into the scale advantages of increasingly faster CMOS.
SiEnergy Systems is developing thin film low temperature SOFC that brings efficient, and affordable clean energy systems for broad application.
SoundCure has developed an FDA-Cleared consumer medical technology offering breakthrough, customized sound therapy and complete tinnitus care to the 16% of adults in the U.S. that suffers from this often debilitating condition.
Developing a MRAM computer memory that has demonstrated superior performance over other memories and is seeking to become the first universal memory technology in the $70 billion computer memory market.
Whitewood Encryption Systems Inc. builds next-generation systems of data encryption that leverage advanced cryptography technologies emerging from U.S. centers of research excellence.